190 related articles for article (PubMed ID: 34478146)
1. Methods for Functional Characterization of FcRn Interactions with Therapeutic Antibodies and Fc-Fusion Proteins.
Chung S; Lin YL; Nguyen V; Liu C
Methods Mol Biol; 2022; 2313():295-303. PubMed ID: 34478146
[TBL] [Abstract][Full Text] [Related]
2. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
3. Development of a label-free FcRn-mediated transcytosis assay for in vitro characterization of FcRn interactions with therapeutic antibodies and Fc-fusion proteins.
Chung S; Lin YL; Nguyen V; Kamen L; Zheng K; Vora B; Song A
J Immunol Methods; 2018 Nov; 462():101-105. PubMed ID: 30030147
[TBL] [Abstract][Full Text] [Related]
4. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
5. Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.
Jaramillo CAC; Belli S; Cascais AC; Dudal S; Edelmann MR; Haak M; Brun ME; Otteneder MB; Ullah M; Funk C; Schuler F; Simon S
MAbs; 2017 Jul; 9(5):781-791. PubMed ID: 28440708
[TBL] [Abstract][Full Text] [Related]
6. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
Gurbaxani B; Dostalek M; Gardner I
Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
[TBL] [Abstract][Full Text] [Related]
8. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
[TBL] [Abstract][Full Text] [Related]
9. An
Chung S; Nguyen V; Lin YL; Lafrance-Vanasse J; Scales SJ; Lin K; Deng R; Williams K; Sperinde G; Li JJ; Zheng K; Sukumaran S; Tesar D; Ernst JA; Fischer S; Lazar GA; Prabhu S; Song A
MAbs; 2019 Jul; 11(5):942-955. PubMed ID: 30982394
[TBL] [Abstract][Full Text] [Related]
10. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
11. Characterization and screening of IgG binding to the neonatal Fc receptor.
Neuber T; Frese K; Jaehrling J; Jäger S; Daubert D; Felderer K; Linnemann M; Höhne A; Kaden S; Kölln J; Tiller T; Brocks B; Ostendorp R; Pabst S
MAbs; 2014; 6(4):928-42. PubMed ID: 24802048
[TBL] [Abstract][Full Text] [Related]
12. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
[TBL] [Abstract][Full Text] [Related]
13. Application of FcRn binding assays to guide mAb development.
Datta-Mannan A; Wroblewski VJ
Drug Metab Dispos; 2014 Nov; 42(11):1867-72. PubMed ID: 25024401
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review.
Ramdani Y; Lamamy J; Watier H; Gouilleux-Gruart V
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077002
[TBL] [Abstract][Full Text] [Related]
15. Development and applications of AlphaScreen-based FcRn binding assay to characterize monoclonal antibodies.
Wu Q; Lee HY; Wong PY; Jiang G; Gazzano-Santoro H
J Immunol Methods; 2015 May; 420():31-7. PubMed ID: 25837414
[TBL] [Abstract][Full Text] [Related]
16. Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography method.
Müller T; Tasser C; Tesar M; Fucek I; Schniegler-Mattox U; Koch J; Ellwanger K
MAbs; 2023; 15(1):2245519. PubMed ID: 37599441
[TBL] [Abstract][Full Text] [Related]
17. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
Maas BM; Cao Y
MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
[TBL] [Abstract][Full Text] [Related]
18. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
[TBL] [Abstract][Full Text] [Related]
19. The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein.
Suzuki T; Hashii N; Tada M; Ishii-Watabe A
MAbs; 2021; 13(1):1923366. PubMed ID: 34030575
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models.
Valente D; Mauriac C; Schmidt T; Focken I; Beninga J; Mackness B; Qiu H; Vicat P; Kandira A; Radošević K; Rao S; Darbyshire J; Kabiri M
MAbs; 2020; 12(1):1829337. PubMed ID: 33079615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
